OTLK

+ Watchlist + Portfolio

Outlook Therapeutics, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.58
52-Week Range: $0.16 – $2.54
Market Cap: $144.36M
P/E (TTM): —
EPS (TTM): -0.70
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -143.17%
Gross Margin: 0.00%
Operating Margin: -124255.27%
Profit Margin: 0.00%
Current Ratio: 0.81
Debt/Equity: —
Total Debt: $18.43M
Free Cash Flow: $-37.36M
Revenue Growth: -99.40%
Earnings Growth: —
Enterprise Value: $151.55M

OTLK Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$1.41M
Cost of Revenue	—	—	$0.00	$1.36M
Gross Profit	—	—	$0.00	$57.20K
Research & Development	$42.33M	$26.45M	$41.76M	$27.18M
Selling, General & Admin	$20.74M	$26.67M	$29.94M	$39.94M
Operating Expenses	$63.07M	$53.13M	$71.70M	$67.12M
Operating Income	-$63.07M	-$53.13M	-$71.70M	-$67.06M
EBITDA	-$64.36M	-$56.40M	-$72.09M	-$63.58M
Pretax Income	-$66.05M	-$58.98M	-$75.36M	-$63.98M
Income Tax	$2.80K	$2.80K	$2.80K	-$1.55M
Net Income	-$66.05M	-$58.98M	-$75.37M	-$62.42M
Diluted EPS	-6.20	-4.80	-4.06	-1.79
Diluted Shares	10.60M	12.51M	18.55M	34.80M

OTLK Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.40M	$23.39M	$14.93M	$8.08M
Receivables	—	—	$0.00	$1.49M
Inventory	—	—	$0.00	$3.34M
Current Assets	$27.52M	$30.98M	$27.42M	$17.39M
Total Assets	$28.53M	$32.30M	$28.82M	$18.58M
Current Liabilities	$19.73M	$46.73M	$42.55M	$45.81M
Total Debt	$10.96M	$35.56M	$29.74M	$30.19M
Total Liabilities	$19.79M	$46.74M	$101.90M	$50.77M
Retained Earnings	-$408.94M	-$467.92M	-$543.28M	-$605.71M
Shareholders' Equity	$8.74M	-$14.44M	-$73.08M	-$32.19M
Working Capital	$7.79M	-$15.75M	-$15.14M	-$28.43M
Net Debt	—	$12.16M	$14.51M	$21.86M

OTLK Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$56.67M	-$42.97M	-$68.79M	-$51.83M
Free Cash Flow	-$56.67M	-$42.97M	-$68.79M	-$51.83M
Depreciation & Amortisation	$204.69K	$44.19K	$113.86K	$117.05K
Stock-Based Compensation	$7.71M	$5.55M	$5.39M	$8.90M
Financing Cash Flow	$59.59M	$48.97M	$60.33M	$44.98M
Net Change in Cash	$2.92M	$6.00M	-$8.46M	-$6.84M

OTLK Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$1.51M	-$91.79K	-$1.21M	$127.44K	$8.70K
Cost of Revenue	$0.00	$439.81K	$916.51K	$29.63K	$149.33K	$16.96K
Gross Profit	$0.00	$1.07M	-$1.01M	-$1.24M	-$21.89K	-$8.27K
Research & Development	$4.41M	$7.13M	$5.98M	$3.63M	$4.50M	$3.25M
Selling, General & Admin	$7.98M	$9.68M	$10.33M	$8.61M	$9.50M	$7.55M
Operating Expenses	$12.39M	$16.81M	$16.31M	$12.25M	$14.01M	$10.80M
Operating Income	-$12.39M	-$15.75M	-$17.31M	-$13.48M	-$14.03M	-$10.81M
EBITDA	-$12.36M	-$15.72M	-$14.55M	-$13.45M	-$14.00M	-$10.80M
Pretax Income	-$46.35M	-$20.15M	-$14.85M	-$23.06M	-$4.45M	-$20.32M
Income Tax	$2.80K	$0.00	-$1.55M	—	$0.00	$0.00
Net Income	-$46.36M	-$20.15M	-$13.29M	-$23.06M	-$4.45M	-$20.32M
Diluted EPS	-1.50	-0.55	—	-0.38	-0.05	-0.15
Diluted Shares	30.87M	36.96M	—	60.20M	81.84M	136.74M

OTLK Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$7.56M	$8.90M	$8.08M	$8.68M	$7.75M	$11.24M
Receivables	—	$1.75M	$1.49M	$114.61K	$2.72M	$1.64M
Inventory	$3.60M	$4.13M	$3.34M	$3.46M	$3.34M	$5.04M
Current Assets	$17.81M	$21.10M	$17.39M	$17.17M	$20.90M	$23.17M
Total Assets	$19.08M	$22.39M	$18.58M	$18.24M	$21.89M	$26.18M
Current Liabilities	$24.82M	$31.49M	$45.81M	$49.06M	$38.88M	$28.68M
Long-Term Debt	$21.05M	$20.44M	—	—	$11.12M	—
Total Debt	$33.32M	$34.70M	$30.19M	$36.89M	$27.19M	$18.43M
Total Liabilities	$51.54M	$59.58M	$50.77M	$56.79M	$50.89M	$36.58M
Retained Earnings	-$572.26M	-$592.42M	-$605.71M	-$628.77M	-$633.22M	-$653.54M
Shareholders' Equity	-$32.46M	-$37.19M	-$32.19M	-$38.55M	-$28.99M	-$10.39M
Working Capital	-$7.02M	-$10.39M	-$28.43M	-$31.89M	-$17.98M	-$5.51M
Net Debt	$25.49M	$25.54M	$21.86M	$27.98M	$19.22M	$6.98M

OTLK Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$16.58M	-$11.90M	-$12.38M	-$14.94M	-$7.83M	-$21.01M
Free Cash Flow	-$16.58M	-$11.90M	-$12.38M	-$14.94M	-$7.83M	-$21.01M
Depreciation & Amortisation	$29.10K	$29.41K	$29.74K	$30.07K	$30.42K	$13.79K
Stock-Based Compensation	$1.72M	$1.68M	$1.82M	$881.15K	$757.48K	$791.67K
Financing Cash Flow	$18.44M	$13.25M	$11.56M	$15.53M	$6.90M	$26.60M
Net Change in Cash	$1.85M	$1.34M	-$817.73K	$594.34K	-$929.20K	$3.49M

Market Snapshot

About

Outlook Therapeutics, Inc. is a biopharmaceutical company developing therapies for retinal diseases. The company focuses on ONS-5010, a formulation of bevacizumab for intravitreal injection to treat wet age-related macular degeneration and other retinal conditions. Outlook Therapeutics aims to provide ophthalmic treatments that improve outcomes for patients with vision-threatening diseases.